IP41-28: Disitamab Vedotin plus BCG intravesical instillation in patients with HER2 high expression high-risk non-muscle invasive bladder cancer(HR-NMIBC): efficacy and safety results from the phrase II Formula-01 trial

IP41-28: Disitamab Vedotin plus BCG intravesical instillation in patients with HER2 high expression high-risk non-muscle invasive bladder cancer(HR-NMIBC): efficacy and safety results from the phrase II Formula-01 trial

Saturday, May 16, 2026 1:00 PM to 3:00 PM · 1 hr. 59 min. (America/New_York)
147A
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!